Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting on positive data gathered from the phase 1 portion of its Acclaim-1 clinical trial. The trial is designed to evaluate the company’s proprietary lead product candidate, REQORSA(R) Immunogene Therapy, in combination with Tagrisso(R) in … Continue reading InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Results of Phase 1 Clinical Trial Will Be Published at ASCO Meeting